UCL’s Novel Approach to Research in Biologically-Relevant Models
News Mar 19, 2014
Cellectricon will co-host a webinar with top researchers at University College London (UCL). The webinar will explore the use of primary cells as a biologically-relevant model for biomedical research, and highlight the new high-throughput techniques and phenotypic screening approaches that are used by UCL to investigate cellular processes in such cells.
The paradigm shift which proposes the use of primary cell types, rather than traditional transformed cell lines, provides a more physiologically accurate view and could help reduce the current high attrition rate in drug discovery programmes.
Offering participants a rare opportunity to hear first-hand from leading researchers, the webinar, entitled ‘Novel approaches for the study of cellular processes in biologically-relevant model systems’, will take place on March 27, 11am-12pm EDT.
To register, please visit www.cellecticon.com/events.
Participants will hear from Dr Robin Ketteler, Group Leader, and Dr Catia Andreassi, Senior Scientist, at the MRC Laboratory for Molecular Cell Biology, UCL, who will provide listeners with an expert insight into the mechanisms of axonal mRNA transport, a vital process for the maintenance of precise neuronal networks in the brain.
The session will go on to reveal how Dr Ketteler’s team are using combinatorial approaches to investigate cellular regulation mechanisms in primary neurons, and how these methods have enabled the group to identify a novel regulatory element that directs mRNA localization and translation.
Attendees of this webinar will gain an educational and eye-opening overview of new techniques that can be used successfully to drive biomedical research in biologically-relevant models.
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE
Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug ScreeningNews
A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE